Skip to main content
Equibles
SRPT logo

SRPT · Sarepta Therapeutics, Inc.

Track SRPT — free

Use SRPT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$23.12 +1.79 (+8.39%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$2.33B
Shares
105.63M

SRPT metrics

70 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$21.33
Market cap
$2.33B

Price action

19 metrics
Price change (1W)
+12.7%
Price change (30D)
+34.3%
Price change (3M)
+31.3%
Price change (6M)
+34.4%
Price change (YTD)
-0.9%
Price change (1Y)
+17.2%
Trailing year
Price change (5Y)
-73.1%
52-week high
$24.45
52-week low
$14.86
Change from 52-week high
-12.8%
Change from 52-week low
+43.5%
Annualized volatility
80.3%
Beta
2.1
RSI (14D)
67.3
Price vs SMA 50
+19.6%
Price vs SMA 200
+11.6%
Avg volume (3M)
3.33M
Relative volume
0.8
Average dollar volume
$58.27M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
105.63M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.2×
reciprocal yield 84.7%
P / book
1.5
reciprocal yield 65.5%
FCF yield
3.5%
TTM · current market cap
Buyback yield
—
P / FCF
28.5
reciprocal yield 3.5%
P / operating cash flow
21.0
reciprocal yield 4.8%
Earnings yield
-5.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
4.3×
reciprocal yield 23.3%
EV / revenue historical average (5Y)
5.9×
reciprocal yield 16.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
98.8%
Operating margin
-7.3%
Trailing 12 months
Net margin
-6.9%
Gross profit (TTM)
$1.02B
Operating profit (TTM)
−$143.25M
Net income (TTM)
−$136.72M
Trailing 12 months
Diluted EPS (TTM)
$-1.60
FCF margin
4.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.03

Growth

11 metrics
Revenue growth YoY
-34.3%
Year over year
Net income growth YoY
-102.5%
Revenue (TTM)
$1.97B
Trailing 12 months
EPS growth YoY
-102.6%
Shares change YoY
-1.1%
Year over year · fewer shares
Revenue CAGR (3Y)
+33.1%
Revenue CAGR (5Y)
+32.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-8.9%
Return on assets
-4.3%
Debt / equity
—
Current ratio
4.4
EBITDA (TTM)
−$98.54M
Free cash flow (TTM)
$81.85M
Quick ratio
2.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$571.15M
Total assets
$3.19B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$111.01M
Capital expenditures (TTM)
$29.16M
R&D (TTM)
$789.44M
SG&A (TTM)
$436.74M
Stock compensation (TTM)
$98.81M
R&D / revenue
40.0%
Stock compensation / revenue
5.0%

Ownership (13F)

3 metrics
13F filers
330
13F filer change QoQ
-20
Institutional ownership
107.0%

Short interest

3 metrics
Short interest
25.6%
Latest settlement · 9.1 days to cover
Days to cover
9.1d
Short-squeeze score
81 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 873303 CUSIP 803607100 13F (30d) 268 filings 263 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)